Skip to Content
Find More Like This
Return to Search

Toroidal mesoporous silica nanoparticles (TMSNPs) and related protocells

United States Patent

9,855,217
January 2, 2018
View the Complete Patent at the US Patent & Trademark Office
Sandia National Laboratories - Visit the Intellectual Property Management and Licensing Website
In one aspect, the invention provides novel monodisperse, colloidally-stable, toroidal mesoporous silica nanoparticles (TMSNPs) which are synthesized from ellipsoid-shaped mesoporous silica nanoparticles (MSNPs) which are prepared using an ammonia basecatalyzed method under a low surfactant conditions. Significantly, the TMSNPs can be loaded simultaneously with a small molecule active agent, a siRNA, a mRNA, a plasmid and other cargo and can be used in the diagnosis and/or treatment of a variety of disorders, including a cancer, a bacterial infection and/or a viral infection, among others. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.
Brinker; C. Jeffrey (Albuquerque, NM), Lin; Yu-Shen (Albuquerque, NM)
STC. UNM (Albuquerque, NM), National Technology & Engineering Solutions of Sandia, LLC (Albuquerque, NM)
15/ 023,110
20160338954
September 18, 2014
STATEMENT REGARDING FEDERAL FUNDING This invention was made with government support under DE-AC04-94AL85000 awarded by the U.S. Department of Energy and U01 CA15179201 awarded by the National Institutes of Health. The government has certain rights in the invention.